• Home
  • About Us
  • List of Health Insurance Companies

Health Plan News

Timely Health Plan News and Commmentary.

Health Plan News
Home Healthcare Plan News Douglas Pharmaceuticals announces results from Phase 2 trial of R-107 in subjects with Treatment Resistant Depression

Douglas Pharmaceuticals announces results from Phase 2 trial of R-107 in subjects with Treatment Resistant Depression

Posted on December 22, 2021 Written by Annalyn Frame

Douglas Pharmaceuticals Ltd (Douglas), a privately held New Zealand-headquartered pharmaceutical company, today announced positive top-line data from its multinational, randomized, placebo-controlled, double-blind Phase 2 study of R-107 designed to investigate the efficacy and safety of R-107 (ketamine 30, 60, 120 or 180 mg) versus placebo for TRD. The study was carried out in New Zealand and Australia, Singapore, Taiwan, and 2021. 168 patients were randomized.

TRD can be defined as the absence of clinically meaningful improvement in depression despite adequate doses at least two antidepressant drugs, administered for a reasonable duration and with good treatment adherence. TRD patients have limited treatment options.

Participants were subject to an open-label enrichment phase for one week. They received R-107 open label 120 mg/day for five days. Double-blind placebo was given to those who showed improvement in depression. They were randomly assigned to receive R-107 open-label 120 mg/day for 5 days. Primary endpoint was the change in depression ratings, Montgomery-Asberg Depression Rating Scales (MADRS).

The enrichment phase saw 73% (168/231) TRD patients quickly remit (MADRS score =12 within one week of open-label R-107 120mg daily treatment). During the enrichment phase, the mean MADRS scores dropped from 31 to 13.

Primary efficacy analysis revealed that 180 mg dosage group had a statistically significant reduction in MADRS score of 6.1 points compared to the placebo group (p=0.019). The MADRS score reductions in the 30 mg, 60mg, and 120m mg groups were 1.9, 0.75, and 4.5 points, respectively, as compared with placebo. These differences were not statistically significant.

R-107 was generally well tolerated. Headache, dizziness, anxiety were the most frequent TEAEs in all dose groups (>10% overall). The study did not report any product-related Serious Adverse Events.

Douglas plans to begin Phase 3 study in 2022 using the best dosing protocol as confirmed by Phase 2 studies.

Douglas Chief Scientific Officer Dr Peter Surman commented that he saw a clear dose-response relationship from the efficacy data. This makes it possible to select the optimal dosing protocol in the Phase 3 study. We are excited to move R-107 development into pivotal trials thanks to the compelling data of the BEDROC trial. This includes both the speed and durability of the response. We thank all the investigators who participated in the study, particularly for adapting to the Covid-19 pandemic. We look forward in continuing R-107 development with the goal to bring a new, effective treatment for the millions of TRD patients.

Jeff Douglas, Douglas’ Managing Director, stated that R-107 has “cleinically meaningful efficacy” as an anti-depressant, making it an ideal therapy for those who have suffered from TRD for many years without any relief. The quick recovery of mood within one week is a major advantage over current treatments, which can take up to six weeks.

Professor Paul Glue MD, University of Otago Hazel Buckland Professor and Chair of the Trial Steering Committee at BEDROC said, “As a researcher and a clinician who treats many patients suffering from TRD, these data are really encouraging.” R-107’s rapid onset of treatment response and its excellent tolerability compared to other methods of ketamine dosing is especially impressive. R-107, if confirmed in pivotal studies, could have a major impact on the way we treat patients with TRD.

R-107Douglas has been developing R-107, an oral treatment for depression that is fast acting. Ketamine is an antagonist of the NMDA receptor. R-107 has been formulated to release ketamine slowly and steadily over 12 hours. This helps to minimize psychotomimetic side-effects that can be associated with other ketamine dosage forms.

Phase 2 BEDROC study key results

Average total MADRS change from Day 1 through Day 92 vs. placebo group
R-107 180 mg group: 6.1, p=0.019
R-107 120 mg group: 4.5, p=0.083
R-107 60 mg group: 0.7, p=0.785
R-107 30 mg group: 1.9, p=0.450
Rapid-acting antidepressant action in enrichment phase (open label 120 mg daily).
73% (168/231) TRD subject responded to enrichment treatment with a MADRS score of =12, and a reduction of >=50% on Day 8.
The MADRS changes from Day 1 to Day 8 are 31 to 13, with a difference 18 (n=231)
Incidence of TEAEs in randomization phase (% patient):
R-107 180 mg group: 94%
R-107 120 mg group: 81%
R-107 60 mg group: 77%
R-107 30 mg group: 65%
Placebo group: 70%

Filed Under: Healthcare Plan News

Recent News

  • Sharon J. Alvis Appointed as New CEO of Sendero Health Plans September 25, 2023
  • Delta Dental of Arkansas Receives Prestigious Governor’s Quality Award September 25, 2023
  • Cigna Healthcare Commits $1 Million to Combat Food Insecurity Among Seniors September 25, 2023
  • Canadians Spend 2.5 Times More Time Navigating Health and Benefits than with Doctors September 25, 2023
  • BORN Ontario Provides Update on Cybersecurity Incident Impacting 3.4 Million Individuals September 25, 2023
  • Gravie Names Andrew Reeves as Senior Vice President and General manager of Gravie ICHRA August 31, 2023
  • Evernorth Care Group expands care to more seniors in Arizona August 31, 2023
  • Findhelp and Rural Health Association of Tennessee will Partner with TennCare in Addressing Non-Medical Factors of Tennesseans August 31, 2023
  • Blue Cross Blue Shield of Minnesota provides grant funding to first-time homeowners in partnership with Twin Cities Habitat for Humanity August 31, 2023
  • EmpiRx Health Applauds Blue Shield of California’s Adoption of a Value-based Model for Prescription Drugs, Announces a Four-Point Plan To Accelerate PBM Transformation August 24, 2023

About Annalyn Frame

Annalyn Frame
Editor-in-Chief, Health Plan News

Annalyn Frame
Editor-in-Chief, Health Plan News

Annalyn Frame is a dedicated registered nurse and accomplished healthcare journalist known for her commitment to promoting accessible and accurate healthcare information. With a unique blend of medical expertise and editorial prowess, Annalyn serves as the Editor-in-Chief of Health Plan News, a leading online platform at the forefront of disseminating essential insights into the ever-evolving landscape of health plans, wellness strategies, and healthcare policy.

Professional Background:
Annalyn's journey in healthcare began as a passionate registered nurse, where she honed her clinical skills and developed a deep understanding of patient care. Her experience in various healthcare settings, ranging from bustling urban hospitals to rural community clinics, has given her a comprehensive perspective on the challenges and opportunities within the industry.

Driven by her desire to bridge the gap between medical knowledge and public awareness, Annalyn transitioned into healthcare journalism. Her keen ability to dissect complex medical concepts and translate them into easily digestible content quickly set her apart as a prominent voice in the field. Her articles, renowned for their clarity and accuracy, have empowered individuals to make informed decisions about their health and well-being.

Editorial Leadership:
As the Editor-in-Chief of Health Plan News, Annalyn Frame brings her healthcare expertise to the forefront. Under her guidance, the publication has become a trusted resource for professionals and consumers alike, offering timely updates on health insurance trends, legislative changes, cost-saving strategies, and innovative healthcare solutions. Annalyn's commitment to journalistic integrity ensures that readers receive information that is not only up-to-date but also reliable, enabling them to navigate the complexities of healthcare with confidence.

Advocacy and Impact:
Beyond her role as an editor, Annalyn remains a staunch advocate for accessible healthcare and health literacy. She frequently participates in community health workshops, seminars, and public speaking engagements, where she empowers individuals with the knowledge they need to take charge of their health. Annalyn's dedication to improving healthcare access extends to her volunteer work with underserved populations, where she leverages her nursing background to provide hands-on care and education.

Education:
Annalyn Frame holds a Bachelor of Science in Nursing (BSN) degree from a respected institution. Her academic foundation, coupled with her hands-on experience, allows her to offer a well-rounded perspective on healthcare matters.

Annalyn Frame's dynamic blend of nursing expertise and editorial leadership has made her a driving force in both healthcare and journalism circles. Her unwavering commitment to delivering accurate, approachable healthcare information through her role as Editor-in-Chief of Health Plan News underscores her mission to empower individuals and promote positive change within the healthcare industry.

Search Our Site

Ketamine Therapy Dallas
Ketamine Treatment Clinic Dallas

Categories

  • AARP
  • Blue Cross Blue Shield
  • Canadian Health Care System
  • CIGNA HealthCare
  • COVID-19
  • Facilities And Providers
  • FDA
  • Health Clinics
  • Healthcare Companies
  • Healthcare Plan News
  • Humana
  • MedBasics
  • Medical And Healthcare
  • Medicare
  • Senior News
  • The SCOOTER Store

Pages

  • 1199 National Benefit Fund
  • A Little about Drug Preparation and Formulation Development
  • About Us
  • Achieve Your Weight Goals with Advanced Thermogenic with NMN
  • Affordable Health Insurance
  • Anavar: A Deep Dive into Athletic Benefits, Potential Side Effects, and Weight Loss Applications
    • Anavar Cycle: Benefits, Dosages, and Side Effects
    • Deca Durabolin vs Anavar: Comparing Performance Enhancers
  • Benefits of Hiring a Senior Caregiving Service
  • Catastrophic Health Insurance
  • Cheap Health Insurance
  • Cheap Health Insurance Plans
  • Child Health Insurance Plans
  • Choosing a Health Insurance Plan
  • Christian Health Insurance
  • Dental Assistants and Their Future
  • Disclaimer
  • Dr. Howard Bellin: Questions about Rhinoplasty
  • Elite Health Online Dual Stack approach: Unlock your weight loss potential
  • Finding the Right Dentist
  • Get Your Winks in Blink
  • Health Insurance
  • Health Insurance Plans For Family
  • Health Sharing Plans
  • Healthcare and Hospitals: Disinfection is Key
  • High Deductible Health Plans
  • Home Care Employment in Arizona
  • Hormone Replacement Therapy
    • Hormone Replacement Therapy (HRT): Balancing the Benefits, Side Effects, and Menopausal Relief
    • Hormone Replacement Therapy: Benefits & Considerations
  • How A Medical Weight Loss Plan Can Help You Get The Figure You Want
  • How Ketamine Therapy Helps Fight Depression
  • How Orthotic Insoles Improve Your Health
  • Individual Health Insurance Plans
  • Ketamine Uses and Benefits
  • List of Health Insurance Companies
  • Low Income Health Insurance
  • Medical Research Consultants
  • Menopause and HRT
  • Nicotinamide Adenine Dinucleotide – Unleashing Vital Molecule Power for Optimal health
  • Oxytocin Benefits
    • Oxytocin: The Love Hormone Decoded
  • Oxytocin Benefits and Hormone Therapy
  • Peptides: The Future of Health and Wellness
  • Personal Lubricants for Women – Liven Up Your Life!
  • Phentermine: Benefits, Usage, and Potential Side Effects
  • Privacy Policy
  • Private Health Insurance Plans
  • Rapamycin, the anti-aging marvel and its multidimensional health benefits
  • Rhesus Negative
  • Self Employed Health Insurance
  • Semaglutide: A Safe and Effective Alternative to Surgical Weight Loss
    • Semaglutide: A Revolutionary Treatment Explored
    • Semaglutide: Bridging Diabetes Treatment and Weight Loss While Managing Side Effects
  • Short Term Health Insurance Plans
  • Student Health Insurance Plans
  • Temporary Health Insurance
  • Terms of Use
  • Testosterone Replacement Therapy Insights
    • Testosterone for Females: Balancing Health & Wellness
  • Testosterone Therapy: Weighing the Benefits, Risks, and Identifying Symptoms
  • The Basic Building Blocks For a Sustained, Healthy Diet
  • The Importance of Clinical Study Software
  • The Marvels and Misgivings of Rapamycin: A Glimpse into Anti-aging and Longevity Benefits
  • The Use of Post Cycle Therapy Supplements
  • Travel Health Insurance
  • Ultimate Guide for Anavar Cycles
  • Understanding Metformin: Benefits and Insights
  • Understanding Nandrolone: Benefits and Uses
    • Nandrolone for Joint Pain: Efficacy, Benefits, and Considerations
    • Nandrolone: From Muscle Building to Therapeutic Uses and Side Effects
  • Unleash your Potential with Nandrolone & Deca Durabolin
  • Unleashing Glutathione’s Power: The Key to Anti-Aging and Health
  • Unlocking Testosterone’s Power: A Comprehensive Guide to Better Health

Copyright © 2023 - Privacy Policy - Terms of Use - Disclaimer